Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine in pulmonary arterial hypertension with right heart failure and cost-utility analysis
ChiCTR2000034928Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivabradine in pulmonary arterial hypertension (PAH) and Right heart dysfunction (RHF), sponsored by The Second Xiangya Hospital. Primary endpoints: 6-minute walk distance, Echocardiography and 4 more. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
ivabradine
03
Conditions
pulmonary arterial hypertension (PAH)Right heart dysfunction (RHF)
Beyond the preview
Go deeper on ChiCTR2000034928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034928.